{"id":"W4387263732","doi":"10.1158/1078-0432.24229199","title":"Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Amgen Canada; Sanofi; Amgen","keywords":"Abiraterone acetate; Cabazitaxel; Prostate cancer; Medicine; Abiraterone; Prostate; Oncology; Cancer; Urology; Internal medicine; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00262493,0.00170409,0.00156476,0.0008904677,0.0007005606,0.002096594,0.00132789,0.001509647,0.7461443],"category_scores_gemma":[0.0216791,0.001037099,0.001551106,0.001160464,0.000264823,0.00107297,0.000900086,0.001728642,0.1386254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001123218,"about_ca_system_score_gemma":0.002474685,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001284128,"about_ca_topic_score_gemma":0.003936686,"domain_scores_codex":[0.9985556,0.0005298086,0.0002530217,0.0002394873,0.0002704319,0.0001516161],"domain_scores_gemma":[0.9899703,0.006530813,0.0008787188,0.0008830022,0.0009111047,0.0008261608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007014424,0.0003857911,0.0006033764,0.005060372,0.0004055781,0.0001363109,0.0000243898,0.0005898763,0.0004948359,0.001201139,0.9543504,0.02973356],"study_design_scores_gemma":[0.07511176,0.004348339,0.01394847,0.004763798,0.001658531,0.00176019,0.00007518745,0.002178656,0.002636459,0.02053313,0.8728107,0.0001747684],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"dataset","genre_gemma":"dataset","genre_scores_codex":[0.001540574,0.001256924,0.001896097,0.001819349,0.002143579,0.002018678,0.9781773,0.0004798886,0.01066772],"genre_scores_gemma":[0.01936489,0.003077943,0.01117272,0.00641954,0.003430638,0.01817655,0.8888679,0.001468611,0.04802118],"genre_candidate":"dataset","genre_consensus":"dataset","teacher_disagreement_score":0.7461443,"threshold_uncertainty_score":0.3620943,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02782642088623507,"score_gpt":0.3241552700205218,"score_spread":0.2963288491342868,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}